What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (current)?

Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (current) has grown at a 45.0% compound annual growth rate (CAGR), from $12.4M to $37.8M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Regeneron Pharmaceuticals REGN Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

IncyteINCY

$5.6M-6.6%

Bristol-Myers SquibbBMY

$199M+15.7%

BridgeBio PharmaBBIO

$4.44M-14.8%

ImmunityBio, Inc.IBRX

$7.63M+2.2%

Kymera TherapeuticsKYMR

——

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

See full

Revenue$3.6B+19.0%

Operating income$642.9M+8.7%

Net income$727.2M-10.1%

EPS (diluted)$6.75-7.2%

Balance sheet

See full

Cash & equivalents$3.0B-4.0%

Total debt$2.7B+0.1%

Total equity$31.4B+6.9%

Total assets$40.9B+8.9%

Cash flow

See full

Operating cash flow$1.1B+3.2%

CapEx$230.6M+0.6%

Free cash flow$848.3M+4.0%

Valuation

See full

Market cap$63.95B+17.8%

Enterprise value$63.68B+18.1%

P/E14.5×+2.4×

P/S4.3×+0.4×

Profitability

See full

Gross margin93.9%—

Operating margin24.3%-2.9pp

Net margin29.6%-2.3pp

FCF margin27.6%+5.5pp

Returns & leverage

See full

Return on equity14.5%-1.4pp

Debt / equity0.1×0.0×

Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Regeneron Pharmaceuticals’s 10-K, filed February 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regeneron Pharmaceuticals's operating lease liabilities (current)?: Regeneron Pharmaceuticals (REGN) reported operating lease liabilities (current) of $37.8M in Q4 2025.
What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (current)?: Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (current) has grown at a 45.0% compound annual growth rate (CAGR), from $12.4M to $37.8M.
What does operating lease liabilities (current) mean?: The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.